Retatrutide Studies: Did Phase 1b Check Safety, Phase 2 Check Benefit, and Phase 3 Test More People?
Early tests ask about safety. Middle tests measure help and harm. The last large tests seek firmer answers.
Can retatrutide help people lose weight?
Can retatrutide help people lose weight? Early studies say it may, but the answer is not final. Retatrutide is a weekly test shot for weight loss and type 2 diabetes, and it copies three hormone messages that guide hunger, blood sugar, and fuel use. Just 1 of those messages can slow the stomach after food arrives. Study staff gave the shot in the fat beneath the skin.
For you, the key is that the drug is still being tested.
In a 48-week study, people at the highest amount lost about 24% of their body weight [1]. That was the group’s average, not a promise for you. Nausea and other stomach trouble were common. A small rise in heart rate also appeared. Retatrutide hasn’t been approved for public use. Everyone who received the study drug was in a study with trained staff. The effects and safety page explains those risks. You can also see the paper behind each finding.
What does retatrutide ask the body to do?
Retatrutide copies three hormone messages that help guide hunger and blood sugar [3]. Just 1 action can do more than 1 job. Two messages may lessen hunger while helping the pancreas release insulin when blood sugar is high [6]. The third comes from glucagon, a hormone that can raise blood sugar. Glucagon may also make the body use more fuel [6]. The three actions are meant to work as 1 drug. A 2025 review called the 24% average loss at 48 weeks a large early result [6], and it came from Phase 2, the middle testing step, so it is not final proof.
The three messages do different work.
After a meal, two gut hormones help the pancreas send out insulin [2]. That helps explain why this drug group seldom causes low blood sugar by itself. Glucagon may push blood sugar upward, yet it may also raise fuel use, and it may help clear fat from the liver. In one smaller study, liver fat fell more than 80% [5]. A small fatty part is attached to retatrutide. The fatty part helps a blood protein carry the drug for about a week [4]. These study facts help you follow the hope behind the shot, and they don’t tell anyone to take it.
What has each retatrutide study found so far?
An early safety study enrolled adults with type 2 diabetes. Retatrutide stayed in their blood long enough for a weekly shot. By 12 weeks, those on the drug had lost 8.96 kilograms more than those given a placebo [4]; a placebo is a look-alike shot with no retatrutide.
The middle studies measured blood sugar, body weight, and liver fat.
In the 48-week Phase 2 weight study, the 12 mg group lost an average of 24.2% of body weight. The placebo group lost 2.1% [1]. A 36-week study enrolled adults who had type 2 diabetes. Their blood test for usual blood sugar across a few months fell 2.02 points at 24 weeks. That meant better blood sugar control for the group. Body weight fell 16.94% by 36 weeks in the 12 mg group [2]. In a smaller liver test, staff found 82.4% less liver fat at 24 weeks. By then, 86% had a normal liver-fat level [5]. A 2025 review joined three fair studies with 878 patients. Weight fell 14.33% more than with placebo across all groups [13]. The full results page gives the details. The retatrutide and tirzepatide page explains why separate studies cannot name a winner.
Why might retatrutide differ from older weight drugs?
Retatrutide copies three hormone messages. Some older weight and diabetes drugs copy only 1 message, while others copy two [3][8]. The added message comes from glucagon, a hormone that may make the body use more fuel; this added action could account for the large early weight change.
You cannot call a drug better just because it has an added action.
A 2026 review lists drugs being tested for weight, heart, kidney, and liver disease [8]. Retatrutide is among those that copy three messages. Its Phase 2 weight result was larger than earlier results for this drug group [1][6]. Yet the figures came from separate studies. The people, length, and care differed. You need a study that gives both drugs under the same rules to learn which works better. That study hasn’t reported. Larger studies must also give a firmer account of long-term help and harm [7]. The early result may interest you, but it cannot settle the choice.
Where can you read more about each retatrutide question?
Where can you read more? Start with how the shot may work. The results page tells what changed for people in each study. The amounts and time in the blood page reports what staff gave, but it gives no dose for you. The common questions page gives short answers. Each bracketed number leads to the full list of papers.
The paper beside a claim tells you how firm it is.
Two limits apply throughout the site. As of 2026, retatrutide is in Phase 3, the last large testing step. The FDA, the public drug office, hasn’t approved it [1][6]. The largest reported results came from Phase 2, the middle step, with a few hundred people. The larger Phase 3 studies on the heart, kidneys, weight, and diabetes haven’t reported [7]. A finished study gives an answer from people already tested. A public study listing only tells what doctors still plan to learn.